We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.775 | 0.75 | 0.80 | 0.775 | 0.775 | 0.78 | 745,046 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.52 | 2.12M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/4/2021 07:02 | RNS Number : 4916W Evgen Pharma PLC 26 April 2021 Evgen Pharma Plc ("Evgen" or "the Company") Appointment of Chief Medical Officer Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Glen Clack, MD, FFPM will be joining the Company as Chief Medical Officer effective from 1 May 2021. Dr Clack has over 30 years' experience in oncology and translational medicine, and held various roles within AstraZeneca for almost 20 years. Dr Clack has specialised in early phase oncology clinical development with an emphasis on a number of important cancers and has a wealth of experience in conducting and managing clinical trials. He has successfully provided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation. He has been a lead member of study, clinical development and project teams on multiple trials. Glen is an Honorary Professor of Translational Medicine at the University of Sheffield and an MSc Module Tutor and Honorary Lecturer in Translational Science at the University of Manchester. He has an MB BS from the Royal Free Hospital School of Medicine in London, is a Fellow of the Faculty of Pharmaceutical Medicine at the University of Wales and holds an MD from the University of Sheffield. Dr Huw Jones CEO of Evgen commented: "We are delighted to have someone of Glen's experience and knowledge join our team. As we progress further with our clinical programmes, Glen's depth of understanding in the fields where we are active will be invaluable. Glen will also be a key member of the team involved in leveraging our relationships with our many partners. His unique skillset has seen him take responsibility for a number of large, complex projects and he has published over 50 academic papers on various cancers." | moneymunch | |
25/4/2021 18:48 | Yes Mikri, my share here is different to my SNG stake. But it’s tops. Actually my SNG stake is extremely small now because when I sold I ballsed up and got left with an odd number that will cost me more to sell than forget about... unless a remarkable increase shocks the pickled monkies out of my sandwich box. | 1rookie | |
25/4/2021 18:22 | Positive efficacy data will be massive news for all concerned, and if SFX-01 is fast tracked by UK Gov, let's hope Evgen has already scaled up manufacture so that supplies can be shipped out to India and other countries where Covid appears to be surging out of control. Gla :-) | moneymunch | |
25/4/2021 17:03 | I have a decent size stake here (not as big as my SNG stake but bigger proportionate to the market cap) - seems amazing risk reward considering (a) low market cap and (b) being in a phase II/III trial for covid - so if they come out with good data it will go up x10 within a week. | mikro1 | |
25/4/2021 13:59 | Exciting times muddy, maybe just coincidence but the timing of John Hopkins, Boris and Prof Chalmers could all be highly significant...all the ducks could be lining UP nicely. :-))) | moneymunch | |
25/4/2021 13:30 | MM. Boris said he wants a pill that could be used along side other therapies. We know from the John Hopkins publication SFN was trailed with others and successful in the lab. Hopefully they are just writing up the phase3 trail with this in mind If successful in the 100 patients thus far and with this MC..... interesting times | muddy_40 | |
25/4/2021 13:17 | Maybe this is the week Bumpa, is SFX-01 one of the pills Boris has in mind??? Gl:-) | moneymunch | |
25/4/2021 10:54 | The aim is to secure at least two antiviral drugs, either in a tablet or capsule form, that people who test positive for Covid-19 or who have been exposed to the virus can take at home. The U.K. government is seeking to identify home coronavirus treatments that can be rolled out ahead of the winter flu season, in a bid to curb the spread of infections and limit the impact of new variants. | dlg3 | |
25/4/2021 10:09 | We’ve waited a while, there have been a number of false starts, but this really does feel like we’re now approaching a tipping point. There is plenty of evidence out there of a growing appreciation for the benefits of sulforaphane across many applications. We just need the spark to light the fire. | bumpa33 | |
25/4/2021 07:01 | Once again it appears that SFX-01 and the Star-Covid trial is completely under the radar, which is some what surprising given that interim efficacy data is expected imminently, maybe SFX-01 has been overlooked because it isn't an Anti-viral as such, although there's a raft of research that highlights Sulforaphane's anti-viral properties including the recent research from John Hopkins University and no doubt if Prof Chalmers reports positive efficacy data on SFX-01, then it would be a prime candidate for Boris's Task force and Autumn target for a pill to be taken at home to treat and prevent Covid. Gla ;-) SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway reduces the severity of ARDS, the progressive lung damage observed in COVID-19 patients which can result in the need for invasive ventilation in an intensive care unit. To date, the therapeutic effect of sulforaphane in academic research has focused on its ability to activate the transcription factor Nrf2 by covalently binding to Keap1. The activation of Nrf2 results in the production of a variety of proteins with antioxidative, anti-inflammatory and cytoprotective qualities. More recently two other molecular targets of sulforaphane have been discovered; STAT3 and SHP2. Both of these targets are highly relevant in a wide range of solid tumours and haematological cancers. April 20, 2021 expert reaction to announcement of an Antivirals Taskforce The government has announced the launch of a COVID-19 Antivirals Taskforce that will aim to identify treatments for patients who have been exposed to COVID-19 to stop the infection spreading and speed up recovery time. Dr Stephen Griffin, Associate Professor in the School of Medicine, University of Leeds, said: “An investment in antiviral medications is welcome indeed to complement the huge resource that has been poured into vaccines, although is disappointingly at odds with recent cuts to other UKRI funding schemes. “It would be useful to understand whether this initiative is primarily to repurpose existing medications for COVID treatment clinical trials, or to develop novel treatments through supporting fundamental and translational research. The timescale of the autumn would suggest the latter, yet both would be beneficial in terms of the long term control of SARS-CoV2 infections, especially for those unable to access, or respond to current vaccines. “The proven benefits of dexamethasone, tocilizumab and sarilumab highlight the value of drug repurposing, and these modulators have considerable impact upon the immune-mediated pathology of severe COVID. However, this approach has been far less successful for identifying direct-acting antiviral drugs against SARS-CoV2. The development of such drugs has been long-neglected by pharmaceutical companies, and many of the antivirals in COVID trials were repurposed from bygone programmes targeting e.g. hepatitis C, HIV or influenza. Moreover, the search for effective antiviral treatments has also led to inappropriate off-label use of drugs such as hydroxychloroquine and, more recently, Ivermectin, without any convincing or supportive clinical evidence; these are often combined with other medicines such as antibiotics and vitamin supplements, seemingly at random. “Thus, a concerted boost to the development of novel direct-acting antivirals would be of considerable clinical benefit alongside repurposing, and the timescale for this could be greatly accelerated by the level of resource and logistical support afforded to the vaccine programmes. UK researchers are already identifying novel treatments in the laboratory, making their rapid future development a huge opportunity to help control the pandemic.” Dr Andrew Garrett, Executive VP, Scientific Operations, ICON Clinical Research, said: “The announcement of the formation of a COVID-19 antivirals taskforce is to be welcomed and shows ambition for the UK to be at the forefront of research into the treatment of COVID-19. This is aligned with the concept of clinical trials as a treatment option whereby patients in the UK are given the opportunity to have early access to the potential benefits of new treatments. The RECOVERY trial and other UK studies have shown the willingness of the UK population to take part in SARS-CoV-2 related clinical trials, that may not only benefit themselves, but also lead to better treatment options for others. The antivirals taskforce follows on from the successful vaccine model which delivered well beyond expectations. In this respect it has set a high bar, but it is important to remember that drug development is an inherently risky business. “The highly ambitious target of having at least two effective treatment this year points to the taskforce supporting the re-purposing of existing drugs, and/or the latter stages of development for new targeted drugs, that are already in development. Re-purposed drugs have the advantage of a well characterized safety profile, but are less targeted than new drugs. However it takes time to establish the safety profile of new drugs. “Nonetheless, this government-led initiative is a clear sign that the UK is open for business and is becoming an increasingly attractive place to undertake drug development.” Dr Janet Scott, Clinical Lecturer in Infectious Diseases, MRC-University of Glasgow Center for Virus Research (CVR), and previous Chief Investigator: Glasgow Early Treatment Arm: Favipiravir (GETAFIX), said: What are plausible candidates? What stage of development/investig “The drugs which are the fastest into use, are drugs which are already in use for other diseases. The only current candidate for an antiviral drug which is also oral is Favipriavir. I am leading a trial called GETAFIX in Glasgow “Glasgow Early Treatment arm FAVIPIRAVIR” already and there is also a sister trial ongoing in London. “This drug was developed as an anti- influenza drug in Japan, but has had some early success in trials in China speeding up time to a person clearing the virus from the system and reducing lung damage. “For the monoclonal antibodies, two contenders are : casirivimab or imdevimab. Is it feasible to have an anti-viral treatment by the autumn? What does it mean to ‘supercharge the search for antiviral treatments’ in practical terms? “We already have one drug in clinical trial, so yes in my view with concerted effort it is possible to have results by the autumn. We cannot promise a positive outcome of course, results will be what they will be. Efforts so far to trial oral drugs have been logistically challenging due to prioritising (rightly) vaccine clinical trials and also the hospital based RECOVERY study. So with political will it is certainly possible to have current trials finished and new trials set up. I would advocate however also for putting an effort in parallel, into earlier phase clinical trials to keep the pipeline of new drugs moving, rather than focusing all research money on end stage clinical trials – that is: everything from improving or creating new drugs, through toxicology testing and first in man trials right up to large scale trials to see if the treatments work. That way we can have the first drugs quickly, but then have better improved drugs coming through – in my view it is unwise to assume we will have THE magic bullet on the first go. Viruses can become resistant to drugs as well as vaccines, (especially to monoclonal antibody based drugs) so it is never wise to let the research sit still. “Please see our recent paper on repurposing anti-covid drugs especially the last section on “the way forward” Do anti-virals for mild/moderate disease exist for other diseases? “Yes -aciclovir cream for herpes simplex (cold sores) and oral or IV for chicken pox or varicella zoster. The oldest antiviral, but still a very effective drug, oseltamivir for influenza. What about prophylactics? “We use aciclovir in pregnancy if a woman is not already immune to chicken pox and has been exposed. Any other comments? “This new initiative is very welcome, useful though to fund research at all parts of the pipeline. We do need a well tolerated, oral antiviral that can be used quickly, when a person gets their first symptoms.” Dr Penny Ward, Faculty of Pharmaceutical Medicine, Visiting Professor in Pharmaceutical Medicine, Kings College London, said: “The announced support for a new taskforce focusing on antiviral treatment/prevention of COVID-19 is much welcomed. Antiviral treatment of influenza has been shown to reduce hospitalization and prevent death in epidemic and pandemic waves and a similar, preferably simple to use antiviral, suitable for use in the community can add to the range of interventions critical to enable us to remain on top of the COVID pandemic even in the event of the emergence of viral variants insensitive to vaccines.” What are plausible candidates? What stage of development/investig “There are currently ongoing early phase trials of orally available antivirals, of which the most advanced is molnupiravir. A protease inhibitor developed by Pfizer (PF-07321332) is in phase I trials in the USA. A number of effective combinations of monoclonal antibodies have completed phase III trials, and newer ones from a variety of companies are in phase II studies currently. Although more difficult to deploy, because of the long half life of an antibody treatment, it remains possible to administer these in care homes, or infusion centres close to individuals homes. Is it feasible to have an anti-viral treatment by the autumn? What does it mean to ‘supercharge the search for antiviral treatments’ in practical terms? “As noted above some potential treatments are already in clinical trials and with additional support could perhaps be manufactured and deployed in community based studies in the UK. The UK GP nationwide network has become more adept at managing patients remotely, and this country is an ideal setting in which to conduct such trials. Do anti-virals for mild/moderate disease exist for other diseases? What about prophylactics? “Yes oseltamivir and baloxivir are both approved for the treatment and prevention of influenza as is the inhaled product zanamivir. Anti influenza antivirals can reduce the duration of illness, reduce the rate of hospitalisation and deaths from influenza when given early enough after first onset of disease. COVID can be approached in exactly the same way.” | moneymunch | |
24/4/2021 19:25 | To bring attention on SFX-01's panacea potential to Boris and Matt and co....maybe...Gla :-))) | moneymunch | |
24/4/2021 18:36 | Certainly the decision to RNS that paper begs questions about why..... Muddy, Bumpa, “puzzlement | bocker01 | |
24/4/2021 16:42 | 22/4/21 Scientists cast new understanding of how skin repairs itself University of Manchester scientists have cast new light on how our skin repairs itself, bringing the possibility of regeneration of the organ a step closer. The study team, funded by the Medical Research Council and Helmut Horten Foundation, sho Two transcription factors – In normal conditions, one in every fourth cell isolated from the inner layer of the skin divides but the team achieved&n The effect was achieved without the addition of growth factors. These naturally occurring but difficult to extract molecules are currently used to improve regeneration of skin, joints, and other frequently damaged organs. Instead of growth factors, scientists used sulpharaphane, a compound found in broccoli, Brussels sprouts, and cabbages. Sulforaphane activates the binding of transcriptions factors to specific parts of the DNA, which  While most of the research was done on human cells&nbs “We know that the skin sometimes cannotefficiently&nb “Our findings suggest that the combined activity of both transcription factors is important to maintain the proliferative capacity of these cells (keratinocytes). “Our skin can be easily damaged, whichimpacts th “However, we hope that The research focusses on “basal It is important because the over promotion of cell division in basal layer could create the conditions for skin cancer but the activation of the supra basal .layer may be ‘cancer-proof& One of identified transcription factors is the master regulator of the DNA in skin cells while the other alleviate Working together, the transcription factorsmay protect and improve cell division without transforming them into cancer cells. She added: “A “Our ultimate goal is to improve regeneration of functional skin – and maybe other organs with the a similar endogen “Each organ has a different master regulator of the DNA, which works with the stress response, so we need to keep researching the mechanisms for specific treatments.” The paper ‘In | moneymunch | |
24/4/2021 16:36 | Scientists decode activation mechanism of SHP2 protein that can trigger cancer Download PDF Copy Reviewed by Emily Henderson, B.Sc.Apr 23 2021 There are many different types of cancer, but they all have one thing in common: errors in the signals that control normal cell behavior can cause uncontrolled cell growth and cell division, leading to a tumor. An enzyme called SHP2 plays a key role in this regard. SHP2 is a signaling molecule that in its activated state stimulates cell proliferation. In a normal healthy body, the rates of cell proliferation and cell death are balanced and tumors do not develop. However, if SHP2 becomes too active, the number of cells being created outweighs the number that die, which can lead to the formation of dangerous tumors. Enhanced SHP2 activity resulting from genetic mutations has been shown to play a central role in a number of types of leukaemia. 'It would be of immense value if we could effectively inhibit the SHP2 protein. But if you want to inhibit something, you first have to find out how it is activated,' says Jochen Hub, explaining the issue at the core of this long-standing scientific puzzle. Hub, Professor of Theoretical Physics at Saarland University, specializes in molecular dynamics simulations and his group develops computer models of biological processes. Hub and his research colleague Dr. Massimiliano Anselmi, who is the lead author of the research paper, have been able to simulate the SHP2 activation mechanism. | moneymunch | |
24/4/2021 12:35 | good point that muddy, there have been plenty of research papers over time on the multiple potential benefits of sulforaphane. So why RNS that one...? | bumpa33 | |
24/4/2021 11:34 | Yes indeed muddy, but every chance of success from what we know so far....if Prof Chalmers confirms efficacy then it will be game on....also very interesting to note that the Star-covid trial exploratory objectives is the measurement of IL6 etc in the blood, which has only recently been highlighted by Prof Chalmers in the Management of Hospitalised Covid patients, and also Neutrophil functional studies in isolated cells, where Prof Chalmers has recently placed great emphasis on over the last few months as being highly significant to Respiratory inflammation etc, and highly possible that these objectives have been on going since the start of the trial, blood and cell sample analysis, with outcome/results relevant to the Star trial already known by prof Chalmers???? Gl ;-) "The panel makes a conditional recommendation for IL-6 receptor antagonist monoclonal antibody treatment and high flow nasal oxygen or continuous positive airway pressure in patients with hypoxaemic respiratory failure " Blood Test could help Transform Care for Covid-19 Patients 31/3/21 Professor James Chalmers, from the University of Dundee’s School of Medicine, has been awarded £32,000 from the University’s own Coronavirus Research Fundraising Campaign to develop a simple blood test that could identify those at increased risk of death from Covid-19. Professor Chalmers and his team hope to develop a test that can detect the antimicrobial complex calprotectin, the release of which indicates the potentially harmful presence of neutrophil extracellular traps. Commonly known as NETosis, these are increasingly recognised as a factor in the severity of illness experienced by Covid-19 patients. The researchers will take blood samples from patients with Covid-19 and work with a clinical team to determine whether a rapid “point of care” test is effective and reliable in recognising calprotectin, with the potential to give patients peace of mind and better treatment. Professor Chalmers said, “We are delighted to receive this award, particularly knowing that this funding was provided by the generous support of members of the public. “Our team have looked after many hundreds of patients in hospital with Covid-19 during this pandemic and one of the most difficult aspects is that while most people will recover completely, around a quarter of people admitted to hospital will get worse and end up needing to be treated with extra drugs or require a ventilator. “Thanks to research conducted last year, we think we have found a simple blood test that can spot which people are going to get severe Covid-19, which would let us give better and earlier treatment. But we first need to prove that it works and that we can give results to doctors quickly enough to make a difference. This study will test exactly that.” The University of Dundee Coronavirus Research Fundraising Campaign was launched to assist the scientific community with research that allows us to better understand Covid-19, and future coronaviruses. further information online .................... James D Chalmers @ProfJDChalmers · 31 Mar Lets be honest, when macrophages get in a difficult fight what do they do? They call the neutrophils... only one winner here. Don't let me down twitter neutrophiles..... James D Chalmers @ProfJDChalmers · 1 Apr Thanks to my friends at Yale for the warm welcome and fantastic discussion last night - talking #neutrophils #bronchiectasis #COVID19 James D Chalmers Retweeted The Lancet Respiratory Medicine @LancetRespirMed · 1h NEW Research—Neutr ProfJDChalmers · 1h An international collaborative study involving patients from UK, Spain, Italy and Australia and an incredible collaborative team Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an... thelancet.com Log in ARTICLES|ONLINE FIRST Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study Summary Background Bronchiectasis is predominantly a neutrophilic inflammatory disease. There are no established therapies that directly target neutrophilic inflammation because little is understood of the underlying mechanisms leading to severe disease. Neutrophil extracellular trap (NET) formation is a method of host defence that has been implicated in multiple inflammatory diseases. We aimed to investigate the role of NETs in disease severity and treatment response in bronchiectasis. COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps | moneymunch | |
24/4/2021 11:16 | Then there's SFX-01 hitting breast cancer tumours for 6, what is there not to like with this company. | dutch123 | |
24/4/2021 10:22 | Nice post muddy and very interesting point, would they bother to highlight John Hopkins research by RNS if they were expecting failure, and I'm still intrigued and excited with Boris's ambitious Autumn target and think the timing of his statement could be highly significant to SFX-01....with any luck. ;-)) Ps 102 patients recruited to SFX-01 Covid/ARDS trial as of 16th February 2021....14 days dosing and then 28 days observation takes the first 100 trial patients to the end of March and the likely start of Prof Chalmers preliminary efficacy assessment although some of the exploratory objectives could have been ongoing since the start of the trial, blood and cell analysis etc.....Gla ;-) The trial will test the following hypothesis: Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection). .................... Primary objective: To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia. Outcome measure:7 point ordinal scale measured on Day 15. Secondary Objectives: Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19 Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm Outcome measures: Cumulative incidence of serious Adverse events (SAEs) Discontinuation or temporary suspension of treatment .................... Exploratory objectives (All sites) Biofire analysis of nasal swab or sputum sample Subanalysis of outcomes according to the causative pathogen Exploratory objectives (TAYSIDE ONLY) Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells Neutrophil functional studies in isolated cells Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood | moneymunch | |
24/4/2021 08:08 | If SFX-01's efficacy for Covid/ARDS is confirmed, then it will be exactly what Boris's Task force will be looking for, a pill that can be taken at home, developed by a British Bio, that potentially can prevent Covid as well as a treatment for Covid if it correlates with John Hopkins University stunning recent research on Sulforaphane's effect on Covid/ARDS etc, and so we're going to have significant upside on initial efficacy results and then global recognition if it's fast tracked by Boris and his team.......Evgen's current market cap is £23m and so £1 a share would equate to a market cap of £275m , SNG's market cap rose from c£35m to over £350m on encouraging phase 2 results , and so news from Evgen confirming SFX-01's efficacy for Covid/ARDS would be much bigger news imho especially if it means that it will be fast tracked by UK Gov.......Exciting times.... Gla ;-) | moneymunch | |
23/4/2021 20:23 | Blooming marvelous...:-))) | moneymunch | |
23/4/2021 20:15 | Lol Bumpa, positive efficacy data and fast tracked by Boris is going to be blooming marvelous for all invested, and I'm liking the action too and am pretty certain that good news is imminent....Fingers Crossed.;-)))) marvelous adjective superb; excellent; great:a marvelous show. such as to cause wonder, admiration, or astonishment; surprising; extraordinary. improbable or incredible:the marvelous events of Greek myth. SYNONYMS FOR MARVELOUS 1wonderful. 2wondrous, amaz 3unbelievable. | moneymunch | |
23/4/2021 19:52 | Marvelous? For once I think you might be underselling the prize mm :) Considering the wider small cap mkt, I’m liking the recent price action. | bumpa33 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions